8-K: ALX Oncology Reports Positive Clinical Data and First Quarter 2024 Financial Results

ALX Oncology announced positive clinical trial results for evorpacept and its first quarter 2024 financial results, highlighting progress in its oncology pipeline.

Summary

• ALX Oncology reported its first quarter 2024 financial results, with a net loss of $35.6 million, or $0.71 per share, compared to a net loss of $30.2 million, or $0.74 per share, in the same period last year.
• The company's research and development expenses increased to $31.7 million, up from $24.8 million in the prior year, due to increased clinical development costs and manufacturing of clinical trial materials.
• General and administrative expenses decreased to $6.0 million from $7.4 million in the prior year, primarily due to lower stock-based compensation expenses.
• As of March 31, 2024, ALX Oncology had $184.5 million in cash, cash equivalents, and investments.
• Subsequent to the quarter end, the company raised an additional $26.2 million through an at-the-market offering.
• The company believes its current cash position, recent ATM proceeds, and the ability to draw down an additional $40 million from its term loan will fund operations well into Q1 2026.
• ALX Oncology highlighted positive data from an investigator-sponsored trial of evorpacept in relapsed or refractory B-cell non-Hodgkin lymphoma, showing a 94% overall response rate and an 83% complete response rate in indolent cases.
• The company also announced the acceptance of two evorpacept abstracts at the 2024 ASCO Annual Meeting and the initiation of a Phase 2 trial of neoadjuvant radiation and evorpacept in oropharyngeal cancer.
• Several upcoming clinical milestones for evorpacept were announced, including top-line results from multiple Phase 2 trials in various cancers expected throughout 2024 and early 2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data and a strong financial position, with a clear path to funding operations into 2026. The increase in R&D expenses is expected for a clinical-stage company, and the management commentary is optimistic. The sentiment is very positive, but not a perfect 10 due to the ongoing losses and risks inherent in clinical development.

Positives

• Evorpacept showed very promising clinical activity in B-cell non-Hodgkin lymphoma with a 94% overall response rate and an 83% complete response rate in indolent cases.
• The company has a strong cash position of $184.5 million, with additional funding secured post-quarter, ensuring operations are funded well into Q1 2026.
• Multiple clinical milestones are expected in the near future, including top-line results from several Phase 2 trials.
• The company is expanding its clinical trial pipeline with the initiation of a new Phase 2 trial in oropharyngeal cancer.
• The company has a best-in-class safety profile for evorpacept, allowing for higher dosage with minimal overlapping toxicity in combination treatment settings.

Negatives

• The company reported a net loss of $35.6 million for the quarter, an increase from the $30.2 million loss in the same period last year.
• Research and development expenses increased significantly, driven by higher clinical trial costs and manufacturing expenses.
• The company is still in the clinical stage and is not generating revenue.

Risks

• The company is dependent on the success of its clinical trials, and there is no guarantee that evorpacept will receive regulatory approval.
• The company is incurring significant losses and may need to raise additional capital in the future.
• Clinical trial results may not be as positive as expected, which could negatively impact the company's valuation.
• The company faces competition from other companies developing cancer therapies.

Future Outlook

The company anticipates its current cash position, recent ATM proceeds, and the ability to draw down an additional $40 million from its term loan will fund operations well into Q1 2026. Multiple clinical milestones are expected in the near future, including top-line results from several Phase 2 trials.

Management Comments

• Jason Lettmann, Chief Executive Officer of ALX Oncology, stated that the company entered the quarter with great momentum after achieving a key validating development milestone for evorpacept in Q4 2023.
• Jason Lettmann also mentioned that the first quarter efforts were focused on ensuring optimal clinical and operational execution as the company advances its clinical-stage pipeline.

Industry Context

ALX Oncology is operating in the competitive immuno-oncology space, focusing on CD47 blockade. The positive clinical data for evorpacept positions the company as a potential leader in this area, particularly with its improved safety profile compared to other anti-CD47 molecules. The company is targeting a range of cancers, including both hematologic and solid tumors, which is a common strategy in the immuno-oncology field.

Comparison to Industry Standards

• The 94% overall response rate and 83% complete response rate in indolent R/R B-NHL with evorpacept plus R2 is significantly higher than the historical R2 complete response rate benchmark of 34%, suggesting a potential best-in-class treatment option.
• Other companies in the CD47 space include Forty Seven (acquired by Gilead) and Trillium Therapeutics (acquired by Pfizer), both of which have faced challenges with safety and efficacy. ALX Oncology's evorpacept is designed with an inactive Fc domain to improve safety, which could be a key differentiator.
• The company's focus on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 inhibitors aligns with current trends in immuno-oncology, where combination therapies are often more effective than single agents.
• The company's cash runway into Q1 2026 is relatively strong compared to other clinical-stage biotech companies, providing financial stability for ongoing clinical development.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong clinical data and financial position.
• Employees may be encouraged by the company's progress and financial stability.
• Patients may benefit from the development of new cancer therapies.
• Creditors are likely to view the company's financial position favorably.

Next Steps

• The company will present two evorpacept abstracts at the 2024 ASCO Annual Meeting.
• Top-line results from multiple Phase 2 trials are expected throughout 2024 and early 2025.
• The company plans to initiate a Phase 3 registrational randomized clinical trial for evorpacept in Gastric/GEJ Cancer in Q4 2024.

Key Dates

Keywords

evorpacept, CD47, immuno-oncology, clinical trials, cancer, B-cell non-Hodgkin lymphoma, urothelial carcinoma, gastric cancer, colorectal cancer, oropharyngeal cancer, ASCO, R&D, financial results